Loading...

LBT Innovations

ASX:LBT
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LBT
ASX
A$14M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

LBT Innovations Limited engages in the research and development of technologies for the healthcare and laboratory supply markets in Australia, Switzerland, and the United States. The last earnings update was 57 days ago. More info.


Add to Portfolio Compare Print
LBT Share Price and Events
7 Day Returns
0%
ASX:LBT
-1.8%
AU Medical Equipment
0.5%
AU Market
1 Year Returns
-51.7%
ASX:LBT
-2.8%
AU Medical Equipment
4.9%
AU Market
LBT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
LBT Innovations (LBT) 0% -4.1% -13.6% -51.7% -54.8% -36.4%
AU Medical Equipment -1.8% -0.2% -1% -2.8% 40.5% 105.5%
AU Market 0.5% 1.9% 8% 4.9% 19.5% 6.3%
1 Year Return vs Industry and Market
  • LBT underperformed the Medical Equipment industry which returned -2.8% over the past year.
  • LBT underperformed the Market in Australia which returned 4.9% over the past year.
Price Volatility
LBT
Industry
5yr Volatility vs Market

LBT Value

 Is LBT Innovations undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of LBT Innovations to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for LBT Innovations.

ASX:LBT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:LBT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.93
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.93 (1 + (1- 30%) (0%))
0.953
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.95
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (0.953 * 5.96%)
7.99%

Discounted Cash Flow Calculation for ASX:LBT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for LBT Innovations is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

ASX:LBT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 7.99%)
2019 -8.90 Analyst x1 -8.24
2020 -2.70 Analyst x1 -2.32
2021 2.10 Analyst x1 1.67
2022 6.50 Analyst x1 4.78
2023 7.60 Analyst x1 5.17
2024 8.48 Est @ 11.62% 5.35
2025 9.23 Est @ 8.83% 5.39
2026 9.87 Est @ 6.87% 5.33
2027 10.41 Est @ 5.51% 5.21
2028 10.88 Est @ 4.55% 5.04
Present value of next 10 years cash flows A$27.39
ASX:LBT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= A$10.88 × (1 + 2.31%) ÷ (7.99% – 2.31%)
A$195.99
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$195.99 ÷ (1 + 7.99%)10
A$90.83
ASX:LBT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$27.39 + A$90.83
A$118.22
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$118.22 / 200.93
A$0.59
ASX:LBT Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$0.59
Current discount Discount to share price of A$0.07
= -1 x (A$0.07 - A$0.59) / A$0.59
88.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price LBT Innovations is available for.
Intrinsic value
>50%
Share price is A$0.07 vs Future cash flow value of A$0.58838
Current Discount Checks
For LBT Innovations to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • LBT Innovations's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • LBT Innovations's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for LBT Innovations's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are LBT Innovations's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:LBT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.02
ASX:LBT Share Price ** ASX (2019-04-23) in AUD A$0.07
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 34.61x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.19x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of LBT Innovations.

ASX:LBT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:LBT Share Price ÷ EPS (both in AUD)

= 0.07 ÷ -0.02

-3.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • LBT Innovations is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • LBT Innovations is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does LBT Innovations's expected growth come at a high price?
Raw Data
ASX:LBT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
68.7%per year
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.67x
Australia Market PEG Ratio Median Figure of 359 Publicly-Listed Companies 1.38x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for LBT Innovations, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on LBT Innovations's assets?
Raw Data
ASX:LBT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.14
ASX:LBT Share Price * ASX (2019-04-23) in AUD A$0.07
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.75x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.68x
ASX:LBT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:LBT Share Price ÷ Book Value per Share (both in AUD)

= 0.07 ÷ 0.14

0.51x

* Primary Listing of LBT Innovations.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • LBT Innovations is good value based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess LBT Innovations's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. LBT Innovations has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LBT Future Performance

 How is LBT Innovations expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
68.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is LBT Innovations expected to grow at an attractive rate?
  • LBT Innovations's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • LBT Innovations's earnings growth is expected to exceed the Australia market average.
  • LBT Innovations's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:LBT Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:LBT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 68.7%
ASX:LBT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 44.4%
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:LBT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:LBT Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 23 8 8 1
2022-06-30 17 7 4 1
2021-06-30 11 2 1 1
2020-06-30 3 -3 -2 1
2019-06-30 1 -9 -6 1
ASX:LBT Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 6 -1 -3
2018-09-30 6 0 -3
2018-06-30 6 1 -3
2018-03-31 4 2 -4
2017-12-31 5 3 -6
2017-09-30 6 1 -6
2017-06-30 6 -1 -5
2017-03-31 4 -1 -2
2016-12-31 3 -1 0
2016-09-30 5 4 2
2016-06-30 8 8 4
2016-03-31 7 8 3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • LBT Innovations's earnings are expected to grow significantly at over 20% yearly.
  • LBT Innovations's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:LBT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from LBT Innovations Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:LBT Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30 0.04 0.04 0.04 1.00
2022-06-30 0.02 0.02 0.02 1.00
2021-06-30 0.01 0.01 0.01 1.00
2020-06-30 -0.01 -0.01 -0.01 1.00
2019-06-30 -0.03 -0.03 -0.03 1.00
ASX:LBT Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.02
2018-09-30 -0.02
2018-06-30 -0.02
2018-03-31 -0.03
2017-12-31 -0.04
2017-09-30 -0.04
2017-06-30 -0.04
2017-03-31 -0.02
2016-12-31 0.00
2016-09-30 0.02
2016-06-30 0.03
2016-03-31 0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • LBT Innovations is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess LBT Innovations's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
LBT Innovations has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LBT Past Performance

  How has LBT Innovations performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare LBT Innovations's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • LBT Innovations does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare LBT Innovations's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare LBT Innovations's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
LBT Innovations's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from LBT Innovations Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:LBT Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 6.26 -3.31 3.05
2018-09-30 6.11 -3.00 3.08
2018-06-30 5.96 -2.69 3.11
2018-03-31 3.93 -4.34 2.81
2017-12-31 5.37 -6.00 2.48
2017-09-30 5.65 -5.57 2.18
2017-06-30 5.92 -5.13 1.88
2017-03-31 4.33 -2.34 1.61
2016-12-31 2.73 0.45 1.34
2016-09-30 5.23 2.02 1.42
2016-06-30 7.73 3.58 1.51
2016-03-31 7.03 3.16 1.45
2015-12-31 6.33 2.75 1.40
2015-09-30 4.35 1.54 1.31
2015-06-30 2.37 0.32 1.22
2015-03-31 2.79 0.18 1.16
2014-12-31 3.21 0.03 1.10
2014-09-30 3.60 0.16 1.43
2014-06-30 3.99 0.29 1.76
2014-03-31 5.16 1.26 2.00
2013-12-31 6.34 2.22 2.24
2013-09-30 5.38 1.38 1.98
2013-06-30 4.42 0.53 1.72
2013-03-31 2.70 -0.44 1.66
2012-12-31 0.99 -1.42 1.59
2012-09-30 1.00 -1.29 1.58
2012-06-30 1.02 -1.16 1.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if LBT Innovations has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if LBT Innovations has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if LBT Innovations improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess LBT Innovations's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
LBT Innovations has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LBT Health

 How is LBT Innovations's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up LBT Innovations's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • LBT Innovations is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • LBT Innovations's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of LBT Innovations's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • LBT Innovations has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from LBT Innovations Company Filings, last reported 3 months ago.

ASX:LBT Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 27.58 0.00 5.71
2018-09-30 27.58 0.00 5.71
2018-06-30 29.11 0.00 7.57
2018-03-31 29.11 0.00 7.57
2017-12-31 23.10 0.00 4.23
2017-09-30 23.10 0.00 4.23
2017-06-30 21.39 0.00 3.50
2017-03-31 21.39 0.00 3.50
2016-12-31 22.76 0.00 5.28
2016-09-30 22.76 0.00 5.28
2016-06-30 19.19 0.00 4.68
2016-03-31 19.19 0.00 4.68
2015-12-31 17.75 0.00 6.67
2015-09-30 17.75 0.00 6.67
2015-06-30 15.68 1.00 1.82
2015-03-31 15.68 1.00 1.82
2014-12-31 15.64 0.00 1.55
2014-09-30 15.64 0.00 1.55
2014-06-30 13.56 0.00 1.79
2014-03-31 13.56 0.00 1.79
2013-12-31 12.13 0.00 2.08
2013-09-30 12.13 0.00 2.08
2013-06-30 12.85 0.00 0.88
2013-03-31 12.85 0.00 0.88
2012-12-31 11.40 0.00 2.42
2012-09-30 11.40 0.00 2.42
2012-06-30 12.31 0.00 2.93
  • LBT Innovations has no debt.
  • LBT Innovations had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • LBT Innovations has sufficient cash runway for 1.4 years based on current free cash flow.
  • LBT Innovations has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 73.3% each year.
X
Financial health checks
We assess LBT Innovations's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. LBT Innovations has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LBT Dividends

 What is LBT Innovations's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from LBT Innovations dividends.
If you bought A$2,000 of LBT Innovations shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate LBT Innovations's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate LBT Innovations's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:LBT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:LBT Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2023-06-30
2022-06-30
2021-06-30
2020-06-30
2019-06-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as LBT Innovations has not reported any payouts.
  • Unable to verify if LBT Innovations's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of LBT Innovations's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as LBT Innovations has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess LBT Innovations's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can LBT Innovations afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. LBT Innovations has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LBT Management

 What is the CEO of LBT Innovations's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Brent Barnes
COMPENSATION A$774,000
TENURE AS CEO 2.7 years
CEO Bio

Mr. Brenton Barnes, also known as Brent, has been the Chief Executive Officer and Director of LBT Innovations Limited since August 08, 2016. Mr. Barnes has been the Managing Director of LBT Innovations Limited since September 6, 2016. After beginning his working life with Defense contractor Thales, Mr. Barnes has spent the past 11 years in a variety of roles with Australian medical device manufacturer Cochlear. Following almost four years in the United States as Cochlear's Area Sales Manager (South Texas) and Director of Operations (Americas), Mr. Barnes returned to Sydney in 2011 to take up roles including Director of Recipient Services & Operations (Asia-Pacific) and General Manager of Asia Growth Markets and Operations Director (Asia Pacific).

CEO Compensation
  • Brent's compensation has increased whilst company is loss making.
  • Brent's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the LBT Innovations management team in years:

2.7
Average Tenure
  • The tenure for the LBT Innovations management team is about average.
Management Team

Brent Barnes

TITLE
CEO, MD & Director
COMPENSATION
A$774K
TENURE
2.7 yrs

Ray Ridge

TITLE
Chief Financial Officer
COMPENSATION
A$156K
TENURE
1.7 yrs

Peter Bradley

TITLE
Vice President of Global Business Development
COMPENSATION
A$228K
TENURE
6.5 yrs

Dan Hill

TITLE
Company Secretary
COMPENSATION
A$26K
TENURE
4.4 yrs

Steven Giglio

TITLE
Scientific Director
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure of the LBT Innovations board of directors in years:

2.2
Average Tenure
  • The average tenure for the LBT Innovations board of directors is less than 3 years, this suggests a new board.
Board of Directors

Kate Costello

TITLE
Chairman
COMPENSATION
A$81K
AGE
65
TENURE
1.7 yrs

Brent Barnes

TITLE
CEO, MD & Director
COMPENSATION
A$774K
TENURE
2.7 yrs

Stephen Mathwin

TITLE
Independent Non-Executive Director
COMPENSATION
A$56K
TENURE
12.4 yrs

Caroline Popper

TITLE
Independent Non-Executive Director
COMPENSATION
A$45K
TENURE
7.1 yrs

Simon Arkell

TITLE
Non-Executive Director
TENURE
0.3 yrs

Damian Lismore

TITLE
Non-Executive Director
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by LBT Innovations insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
31. Mar 19 Buy Damian Lismore Individual 28. Mar 19 28. Mar 19 203,716 A$0.08 A$16,697
22. Mar 19 Buy Brenton Barnes Individual 20. Mar 19 20. Mar 19 203,389 A$0.06 A$12,000
02. May 18 Buy Glenn Haifer Individual 27. Apr 18 27. Apr 18 1,666,667 A$0.15 A$249,998
02. May 18 Buy Catherine Costello Individual 27. Apr 18 27. Apr 18 666,667 A$0.15 A$99,999
02. May 18 Buy Caroline Popper Individual 27. Apr 18 27. Apr 18 100,000 A$0.15 A$15,000
02. May 18 Buy Matthew Michalewicz Individual 27. Apr 18 27. Apr 18 333,334 A$0.15 A$50,000
02. May 18 Buy Stephen Mathwin Individual 27. Apr 18 27. Apr 18 200,000 A$0.15 A$30,000
02. May 18 Buy Brenton Barnes Individual 27. Apr 18 27. Apr 18 333,334 A$0.15 A$50,000
X
Management checks
We assess LBT Innovations's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. LBT Innovations has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LBT News

Simply Wall St News

What Kind Of Shareholder Owns Most LBT Innovations Limited (ASX:LBT) Stock?

The big shareholder groups in LBT Innovations Limited (ASX:LBT) have power over the company. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … With a market capitalization of AU$14m, LBT Innovations is a small cap stock, so it might not be well known by many institutional investors.

Simply Wall St -

Should You Be Holding LBT Innovations Limited (ASX:LBT)?

Building up an investment case requires looking at a stock holistically. … Today I've chosen to put the spotlight on LBT Innovations Limited (ASX:LBT) due to its excellent fundamentals in more than one area.

Simply Wall St -

Have Insiders Been Buying LBT Innovations Limited (ASX:LBT) Shares This Year?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So we'll take a look at whether insiders have been buying or selling shares in LBT Innovations Limited (ASX:LBT). … In the last twelve months there was more buying than selling by LBT Innovations insiders

Simply Wall St -

The LBT Innovations Share Price Is Down 60% So Some Shareholders Are Wishing They Sold

Investing in stocks comes with the risk that the share price will fall. … One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … Even though the LBT Innovations share price is down over the year, its EPS actually improved.

Simply Wall St -

How Much is LBT Innovations Limited's (ASX:LBT) CEO Getting Paid?

First, this article will compare CEO compensation with compensation at similar sized companies. … Then we'll look at a snap shot of the business growth. … How Does Brent Barnes's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Does The LBT Innovations Limited (ASX:LBT) Share Price Tend To Follow The Market?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Simply Wall St -

Could LBT Innovations Limited's (ASX:LBT) Investor Composition Influence The Stock Price?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … With a market capitalization of AU$18m, LBT Innovations is a small cap stock, so it might not be well known by many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

What Investors Should Know About LBT Innovations Limited's (ASX:LBT) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is LBT growing fast enough to value financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

These Factors Make LBT Innovations Limited (ASX:LBT) An Interesting Investment

Building up an investment case requires looking at a stock holistically. … Today I've chosen to put the spotlight on LBT Innovations Limited (ASX:LBT) due to its excellent fundamentals in more than one area.

Simply Wall St -

What Kind Of Risk Should You Expect For LBT Innovations Limited (ASX:LBT)?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

LBT Company Info

Description

LBT Innovations Limited engages in the research and development of technologies for the healthcare and laboratory supply markets in Australia, Switzerland, and the United States. It offers MICROSTREAK, an automated culture-plate streaking and inoculation system; and APAS, a platform technology for the automation of culture-plate screening and interpretation. The company was founded in 2004 and is headquartered in Adelaide, Australia.

Details
Name: LBT Innovations Limited
LBT
Exchange: ASX
Founded: 2004
A$14,064,891
200,927,025
Website: http://www.lbtinnovations.com
Address: LBT Innovations Limited
44 Waymouth Street,
Level 8,
Adelaide,
South Australia, 5000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX LBT Ordinary Shares Australian Securities Exchange AU AUD 31. Jul 2006
DB LSM Ordinary Shares Deutsche Boerse AG DE EUR 31. Jul 2006
CHIA LBT Ordinary Shares Chi-X Australia AU AUD 31. Jul 2006
Number of employees
Current staff
Staff numbers
0
LBT Innovations employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 10:33
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/01/10
Last earnings filing: 2019/02/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.